EBNA-1 (p = 0.39) and VCA (p = 0.67) antibody levels did not differ between the groups of untreated (n = 70), glatiramer acetate-treated (n = 14), and interferon-beta-treated (n = 15) patients with CIS/early RRMS. Here, IFNB1 is linked to in situ carcinoma.